{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:29Z","timestamp":1760189129243},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":8879,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scandinavian Journal of Haematology"],"published-print":{"date-parts":[[1985,1]]},"abstract":"<jats:p>27 patients (aged 15\u201355 years) with relapsed acute myelogenous (AML) and lymphoblastic leukaemia (ALL), and with lymphoblastic non Hodgkin's lymphoma (NHL) have been treated with intermediate dose cytosine arabinoside (AraC, 1 g\/m<jats:sup>2<\/jats:sup>q 12h x 12) and 3 d of m\u2010AMSA (20 patients), 90\u2013115 mg\/m<jats:sup>2<\/jats:sup>daily, or daunorubicin (7 patients). 18 of them attained a complete remission (AML 10\/14, ALL 3\/5, NHL 5\/8). 7 patients received consolidation treatment with 1\u20132 courses comprising 4 d of AraC (3 g\/m<jats:sup>2<\/jats:sup>q 12 h x 8) and m\u2010AMSA (90\u2013115 mg\/m<jats:sup>2<\/jats:sup>) on d 5 of each course. 2 patients underwent allogeneic bone marrow transplantation and 9 received no further treatment after remission induction.<\/jats:p><jats:p>In addition to vomiting, fever and conjunctivitis, toxicity in 6 patients included a combination of severe diarrhoea, fever and signs of paralytic ileus. 3 of them died during the pancytopenic phase. The pancytopenic period ranged from 16\u201325 d (median 21 d) after the remission induction and 14\u201321 d (median 19 d) after the consolidation course. Median remission duration was 5 months for those patients who received no treatment after remission induction and &gt;9 months (4+\u201016+ months) for the patients who received consolidation courses. Increased dosages of AraC are active in relapsed leukaemia and lymphoma, although optimal dose and schedule are still undetermined.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1985.tb00748.x","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T22:12:16Z","timestamp":1280959936000},"page":"83-87","source":"Crossref","is-referenced-by-count":30,"title":["Intermediate and high\u2010dose ARA\u2010C and m\u2010AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"34","author":[{"given":"R.","family":"Willemze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"van Hennik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. E.","family":"Fibbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M. M.","family":"Kootte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"van Berkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"Rodenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"issue":"191","key":"e_1_2_1_2_2","article-title":"High dose cytosine arabinoside in the treatment of patients with refractory acute non\u2010lymphocytic leukaemia","volume":"54","author":"Karanes C.","year":"1979","journal-title":"Blood"},{"issue":"141","key":"e_1_2_1_3_2","article-title":"Successful treatment of patients (pts) with refractory acute nonlympocytic leukemia (ANLL) using high dose cytosine arabinoside (HDAraC) with and without anthra\u2010cycline","volume":"58","author":"Herzig RH","year":"1981","journal-title":"Blood"},{"issue":"142","key":"e_1_2_1_4_2","article-title":"High dose cytosine arabinoside (Ara\u2010C) and m\u2010AMSA in refractory acute non\u2010lymphocytic leukemia (ANLL)","volume":"58","author":"Hines JD","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02808.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0609.1982.tb00575.x","article-title":"High dose cytosine arabinoside in the management of refractory acute leukaemia","volume":"29","author":"Willemze R.","year":"1982","journal-title":"Scand J Haematol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O"},{"key":"e_1_2_1_8_2","first-page":"1587","article-title":"A pilot study of high\u2010dose 1\u2010beta\u2010d\u2010arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology","volume":"42","author":"Early AP","year":"1982","journal-title":"Cancer Res"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.93"},{"key":"e_1_2_1_10_2","unstructured":"RohatinerAZS DhaliwalHS SlevinML ListerTA.High dose AraC: response to therapy in acute leukaemia and non\u2010Hodgkin's lymphoma. In:Proc 3rd Int Symp on Therapy of Acute Leukaemias December 11\u201314 1982. Rome p.230."},{"key":"e_1_2_1_11_2","first-page":"215","article-title":"Experience with intermediate and high dose arabinoside in relapsed and refractory acute leukaemia","volume":"26","author":"Willemze R.","year":"1983","journal-title":"Neth J Med"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/143.5.644"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(81)90240-3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811215)48:12<2577::AID-CNCR2820481207>3.0.CO;2-Z"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254596"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb02898.x"},{"key":"e_1_2_1_17_2","first-page":"172","article-title":"The treatment of acute myelogenous leukemia in adults","volume":"19","author":"Lister TA","year":"1982","journal-title":"Semin Hematol"},{"issue":"159","key":"e_1_2_1_18_2","article-title":"Therapy of acute non\u2010lymphocytic leukaemia (ANLL) and first remission: brief intensive consolidation with high dose AraC","volume":"60","author":"Wolff SN","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_19_2","unstructured":"WeilM.The combination of Amsacrin and cytosine arabinoside in the treatment of acute leukemias. In:Amsacrine. Current perspectives and clinical results with a new anticancer agent1983;103\u20137."},{"key":"e_1_2_1_20_2","first-page":"3304","article-title":"Phase I and II trial of 4\u2032\u2010(9\u2010acridinylamino)\u2010methane\u2010sulfon\u2010m\u2010anisidide) in patients with acute leukaemia","volume":"40","author":"Arlin ZA","year":"1980","journal-title":"Cancer Research"}],"container-title":["Scandinavian Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1985.tb00748.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1985.tb00748.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T02:18:08Z","timestamp":1711678688000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1985.tb00748.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1985,1]]}},"alternative-id":["10.1111\/j.1600-0609.1985.tb00748.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1985.tb00748.x","archive":["Portico"],"relation":{},"ISSN":["0036-553X"],"issn-type":[{"value":"0036-553X","type":"print"}],"subject":[],"published":{"date-parts":[[1985,1]]}}}